C3orf54 Inhibitors
C3orf54 Inhibitors are chemical compounds that directly or indirectly lead to the decreased functional activity of the protein C3orf54. The first six inhibitors – U0126, LY294002, SB203580, Wortmannin, SP600125, and Rapamycin – inhibit upstream components of various pathways including the MAPK/ERK, PI3K/AKT, and p38 MAPK pathways. By inhibiting these upstream components, these compounds reduce the functional activity of C3orf54 if it is a downstream effector in these pathways. For instance, U0126 and LY294002 inhibit MEK1/2 and PI3K respectively, preventing the phosphorylation and activation of ERK1/2 and AKT. This inhibits the activity of the MAPK/ERK and PI3K/AKT pathways, leading to decreased functional activity of C3orf54 if it is involved in these pathways.
The remaining six inhibitors– PD98059, Akti-1/2, AZD8055, PF-04691502, GSK690693, and FR180204 – function similarly, acting on the MEK, AKT, mTOR, and ERK components of various signaling pathways. These inhibitors suppress the activities of these components, which directly govern the PI3K/AKT/mTOR, and MAPK/ERK pathways. For example, PD98059 and Akti-1/2 inhibit MEK and AKT1/2 respectively, disrupting the phosphorylation and activation of ERK1/2 and AKT. This leads to the inhibition of the MAPK/ERK and PI3K/AKT pathways, thereby reducing the functional activity of C3orf54 if it is a part of these pathways. Similarly, AZD8055 and PF-04691502 inhibit mTOR and PI3K/mTOR respectively, decreasing the activity of the PI3K/AKT/mTOR pathway. If C3orf54 is directly involved in this pathway, its functional activity is decreased due to these inhibitions. GSK690693 inhibits AKT and FR180204 inhibits ERK, leading to the decreased functional activity of the PI3K/AKT and MAPK/ERK pathways, and subsequently, of C3orf54 if it is directly involved in these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. It reduces the activity of the PI3K/AKT pathway. If C3orf54 is directly involved in this pathway, its functional activity is decreased as a result of this inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK. If C3orf54 is directly involved in the p38 MAPK pathway, its functional activity is reduced due to the inhibition of downstream signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits PI3K. By reducing PI3K activity, it inhibits downstream signaling in the PI3K/AKT pathway, which leads to decreased functional activity of C3orf54 if it is a part of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective JNK inhibitor. By inhibiting JNK, it inhibits the JNK/MAPK pathway and downstream signaling events, leading to reduced functional activity of C3orf54 if it is directly involved in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. It decreases the activity of the PI3K/AKT/mTOR pathway. If C3orf54 is part of this pathway, its functional activity is decreased as a result of this inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. By inhibiting MEK, it reduces the activity of the MAPK/ERK pathway. If C3orf54 is directly involved in this pathway, its functional activity is decreased due to this inhibition. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
Akti-1/2 is an AKT1/2 inhibitor. It inhibits the PI3K/AKT pathway. If C3orf54 is part of this pathway, its functional activity is reduced due to this inhibition. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an mTOR inhibitor. It decreases the activity of the PI3K/AKT/mTOR pathway, leading to decreased functional activity of C3orf54 if it is directly involved in this pathway. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an AKT inhibitor. It inhibits the PI3K/AKT pathway. If C3orf54 is part of this pathway, its functional activity is reduced due to this inhibition. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $108.00 $162.00 $234.00 $924.00 | 45 | |
FR180204 is an ERK inhibitor. It reduces the activity of the MAPK/ERK pathway. If C3orf54 is directly involved in this pathway, its functional activity is decreased due to this inhibition. | ||||||